Acurx Pharmaceuticals, LLC*(ACXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ACXP Acurx Pharmaceuticals, LLC*

Pre-Mkt 09-09 08:59:47 EDT

1.43

+0.01

+0.70%

盘前1.43

+0.000.00%

08:43 EDT

High1.46	Low1.41	Vol88.57K
Open1.41	D1 Closing1.42	Amplitude3.52%
Mkt Cap7.82M	Tradable Cap7.64M	Total Shares5.47M
T/O126.71K	T/O Rate1.66%	Tradable Shares5.34M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ACXP","market":"US","secType":"STK","nameCN":"Acurx Pharmaceuticals, LLC*","latestPrice":1.43,"timestamp":1788897600000,"preClose":1.42,"halted":0,"volume":88565,"hourTrading":{"tag":"盘前","latestPrice":1.43,"preClose":1.43,"latestTime":"08:43 EDT","volume":853,"amount":1223.4881814999999,"timestamp":1788957819351,"change":0,"changeRate":0,"amplitude":0.046224},"delay":0,"changeRate":0.007042253521126767,"floatShares":5342700,"shares":5471300,"eps":-3.0454,"marketStatus":"Pre-Mkt","change":0.01,"latestTime":"09-09 08:59:47 EDT","open":1.41,"high":1.46,"low":1.41,"amount":126707.75794450002,"amplitude":0.035211,"askPrice":1.49,"askSize":195,"bidPrice":1.39,"bidSize":15,"shortable":3,"etf":0,"ttmEps":-3.0454,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788960600000},"marketStatusCode":1,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":1.43,"preHourTrading":{"tag":"盘前","latestPrice":1.43,"preClose":1.43,"latestTime":"08:43 EDT","volume":853,"amount":1223.4881814999999,"timestamp":1788957819351,"change":0,"changeRate":0,"amplitude":0.046224},"postHourTrading":{"tag":"盘后","latestPrice":1.4569,"preClose":1.43,"latestTime":"19:42 EDT","volume":8413,"amount":12239.0527,"timestamp":1788910967579,"change":0.0269,"changeRate":0.018811,"amplitude":0.020979},"volumeRatio":1.0984097746659482,"impliedVol":1.1448,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ACXP","defaultTab":"news","newsList":[{"id":"2666377609","title":"Acurx Pharmaceuticals - Files for Resale of 1,500,000 Common Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377609","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377609?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:28","pubTimestamp":1788899307,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nFWN4500VQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4563","BK4539","ACXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664660228","title":"Acurx Pharma Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2664660228","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664660228?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:16","pubTimestamp":1788293802,"startTime":"0","endTime":"0","summary":"Acurx Pharma announces annual shareholder meetingAcurx Pharmaceuticals will hold its annual shareholder meeting virtually on Oct. 16, 2026.Shareholders will vote to elect two Class II directors for th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL9w65js:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4539","ACXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660747894","title":"Analysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660747894","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660747894?lang=en_us&edition=fundamental","pubTime":"2026-08-20 03:40","pubTimestamp":1787168424,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP) ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-annovis-bio-anvs-and-acurx-pharmaceuticals-acxp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-annovis-bio-anvs-and-acurx-pharmaceuticals-acxp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACXP","BK4137","BK4588","BK4139","XLV","ANVS","BK4563","LABU","BK4539","LU0029874061.USD","LU0128526141.USD","BK4585","HCSG","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660482224","title":"Acurx Pharmaceuticals Receives FDA Conditional Acceptance and Uspto Trademark Allowance for the Company's Brand Name for Ibezapolstat","url":"https://stock-news.laohu8.com/highlight/detail?id=2660482224","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660482224?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:01","pubTimestamp":1786968060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA4R5JMM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4563","ACXP","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659214005","title":"Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659214005","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659214005?lang=en_us&edition=fundamental","pubTime":"2026-08-14 23:10","pubTimestamp":1786720209,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Candel Therapeutics (CADL), Acurx Pharmaceuticals (A...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-candel-therapeutics-cadl-acurx-pharmaceuticals-acxp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-candel-therapeutics-cadl-acurx-pharmaceuticals-acxp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACXP","CADL","BK4563","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144016","title":"Acurx Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144016","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144016?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:31","pubTimestamp":1786714317,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings SummaryAcurx Pharmaceuticals IncACXP.OQreported a quarterly adjusted loss of 53 cents per share for the quarter ended","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B0WI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","BK4539","ACXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659143785","title":"Acurx Pharmaceuticals Q2 EPS $(0.53) Misses $(0.37) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659143785","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659143785?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:02","pubTimestamp":1786705322,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals (NASDAQ:ACXP) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $(0.37) by 43.24 percent. This is a 71.96 percent increase over losses of $(1.89) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61203893/acurx-pharmaceuticals-q2-eps-0-53-misses-0-37-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","BK4539","ACXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659279143","title":"Acurx Pharmaceuticals Q2 EPS USD -0.53","url":"https://stock-news.laohu8.com/highlight/detail?id=2659279143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659279143?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:02","pubTimestamp":1786705321,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nPLXF09J3Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACXP","BK4139","BK4539","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659145854","title":"Press Release: Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659145854","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659145854?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:01","pubTimestamp":1786705260,"startTime":"0","endTime":"0","summary":"STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc.  , a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended June 30, 2026.Highlights of the second quarter ended June 30, 2026, or in some cases shortly thereafter, include:-- In April 2026, the Company announced the closing of a registered direct. offering of 825,085 shares of its common stock (or pre-funded warrants in. lieu thereof) at a purchase price of $3.03 per share (or pre-funded. warrant in lieu thereof) priced at-the-market under Nasdaq rules. In. addition, in a concurrent private placement, the Company issued. unregistered short-term warrants to purchase up to 1,650,170 shares of. common stock. The short-term warrants have an exercise price of $2.78 per. share, and are immediately exercisable upon issuance and will expire. twenty-four months follo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK4022","BK4539","R","BK4139","BK4232","ACXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167881","title":"Acurx Net Loss Flat at $2.26 Million in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167881","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167881?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:16","pubTimestamp":1786652216,"startTime":"0","endTime":"0","summary":"Acurx net loss flat at $2.26 million in Q2 2026Acurx posted a net loss of $2.26 million for the quarter ended June 30, 2026, little changed from a year earlier.R&D expense climbed 104% to $1.07 millio","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL2cHVMV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACXP","BK4139","BK4539","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659158478","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2659158478","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659158478?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:00","pubTimestamp":1786615200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company                                   Symbol     Quarter  Mean  Report Time. ·ADC Ther. Ltd                                   2Q      (.22)   7:30 AM. ·Applied Ind Tech                                 4Q      2.92    6:30 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARX","AVR","ACOG","ACXP","DCGO","BAP","CAPR","STNE","DARE","AMAT","BTBT","CRMD","CLRB","BRUN","CAAP","ELMT","FBRX","ASND","AIT","ALH","ABEO","BAK","CRDL","DRUG","VIPS","AEBI","AVAH","BLTE","CLBT","CAMP","CELC","DEFT","ESEA","ADCT","BIRK","CAN","ARCO","BSP","BEAT","DDS","AIRJ","AEYE","AIRO","ETON","BN","DLO","EVTL","EU","BZAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659626901","title":"ACXP Advances Ibezapolstat Trial in High-Risk C. Difficile Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2659626901","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659626901?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:30","pubTimestamp":1786552242,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Llc ($ACXP) announced an update on their ongoing clinical study. The Phase 2 IBZ-PATHFINDER study tests Acurx Pharmaceuticals...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acxp-advances-ibezapolstat-trial-in-high-risk-c-difficile-patients?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acxp-advances-ibezapolstat-trial-in-high-risk-c-difficile-patients?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACXP","BK4139","BK4563","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658777839","title":"Acurx Pharmaceuticals Inc Expected to Post a Loss of 38 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658777839","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658777839?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:45","pubTimestamp":1786538706,"startTime":"0","endTime":"0","summary":"Acurx Pharmaceuticals Inc <ACXP.OQ> expected to post a loss of38cents a share - Earnings PreviewAcurx Pharmaceuticals IncACXP.OQACXP.Ois expected to  show no change in quarterly revenue when it report","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL8N44916U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","ACXP","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972981","title":"Acurx Says Japan, Mexico Patent Offices Grant New Patents for DNA Polymerase IIIC Inhibitor Antibiotics","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972981","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972981?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:04","pubTimestamp":1786536277,"startTime":"0","endTime":"0","summary":"Acurx says Japan, Mexico patent offices grant new patents for DNA polymerase IIIC inhibitor antibioticsAcurx Pharmaceuticals won new patents in Japan, Mexico covering its DNA polymerase IIIC inhibitor","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL3YqZJ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACXP","BK4563","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658936176","title":"Acurx partners with Leiden University Medical Center to develop its antibiotics","url":"https://stock-news.laohu8.com/highlight/detail?id=2658936176","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658936176?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:11","pubTimestamp":1786363893,"startTime":"0","endTime":"0","summary":"Acurx (ACXP) Pharmaceuticals announced a new scientific partnership with Leiden University Medical Center, or LUMC, in the Netherlands. Prior work ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/acurx-partners-with-leiden-university-medical-center-to-develop-its-antibiotics-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/acurx-partners-with-leiden-university-medical-center-to-develop-its-antibiotics-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4563","ACXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658193501","title":"Acurx Partners with Leiden UMC to Develop First 3D Structure of MRSA PolC Bound to Its Antibiotic Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2658193501","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658193501?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:07","pubTimestamp":1786363642,"startTime":"0","endTime":"0","summary":"Acurx partners with Leiden UMC to develop first 3D structure of MRSA PolC bound to its antibiotic inhibitorAcurx formed a research partnership with Leiden University Medical Center to advance DNA poly","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDL51YL0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ACXP","BK4563","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658115935","title":"Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase Iiic Inhibitor Antibiotics","url":"https://stock-news.laohu8.com/highlight/detail?id=2658115935","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658115935?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:01","pubTimestamp":1786363260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nTUA16J8CP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4563","ACXP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656308879","title":"Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Acurx Pharmaceuticals (ACXP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656308879","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656308879?lang=en_us&edition=fundamental","pubTime":"2026-08-03 23:40","pubTimestamp":1785771605,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Wave Life Sciences (WVE) and Acurx Pharmaceuticals (...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-wave-life-sciences-wve-and-acurx-pharmaceuticals-acxp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-wave-life-sciences-wve-and-acurx-pharmaceuticals-acxp-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ACXP","BK4581","BK4007","LABU","BK4588","WVE","BK4585","XLV","HCSG","BK4539","BK4137","BK4563","XBI","LU0029874061.USD","LU0128526141.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656537612","title":"Acurx Says FDA Open to Single Phase 3 Trial to Support Ibezapolstat CDI NDA Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2656537612","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656537612?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:04","pubTimestamp":1785758696,"startTime":"0","endTime":"0","summary":"Acurx says FDA open to single Phase 3 trial to support ibezapolstat CDI NDA filingAcurx received FDA guidance on its ibezapolstat Phase 3 plan for C. difficile infection, including a possible single-t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDLP8YQD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACXP","BK4563","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656376669","title":"Acurx Pharmaceuticals - Receives FDA Guidance on Single Phase 3 Trial Nda for Ibezapolstat in Cdi","url":"https://stock-news.laohu8.com/highlight/detail?id=2656376669","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656376669?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:00","pubTimestamp":1785758425,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN4400Q1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACXP","BK4563","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acurxpharma.com","stockEarnings":[{"period":"1week","weight":0.0214},{"period":"1month","weight":-0.0714},{"period":"3month","weight":-0.1063},{"period":"6month","weight":-0.7146},{"period":"1year","weight":-0.6533},{"period":"ytd","weight":-0.4257}],"compareEarnings":[{"period":"1week","weight":0.0055},{"period":"1month","weight":-0.0094},{"period":"3month","weight":0.0559},{"period":"6month","weight":0.15},{"period":"1year","weight":0.1805},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.08634},{"month":2,"riseRate":0,"avgChangeRate":-0.144545},{"month":3,"riseRate":0.4,"avgChangeRate":0.164663},{"month":4,"riseRate":0.4,"avgChangeRate":-0.083182},{"month":5,"riseRate":0.4,"avgChangeRate":-0.056147},{"month":6,"riseRate":0.4,"avgChangeRate":0.051493},{"month":7,"riseRate":0,"avgChangeRate":-0.145307},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.071694},{"month":9,"riseRate":0,"avgChangeRate":-0.098427},{"month":10,"riseRate":0.6,"avgChangeRate":0.545147},{"month":11,"riseRate":0.2,"avgChangeRate":-0.181708},{"month":12,"riseRate":0.4,"avgChangeRate":-0.094208}],"exchange":"NASDAQ","name":"Acurx Pharmaceuticals, LLC*","nameEN":"Acurx Pharmaceuticals, LLC*"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Acurx Pharmaceuticals, LLC*(ACXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Acurx Pharmaceuticals, LLC*(ACXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Acurx Pharmaceuticals, LLC*,ACXP,Acurx Pharmaceuticals, LLC*股票,Acurx Pharmaceuticals, LLC*股票老虎,Acurx Pharmaceuticals, LLC*股票老虎国际,Acurx Pharmaceuticals, LLC*行情,Acurx Pharmaceuticals, LLC*股票行情,Acurx Pharmaceuticals, LLC*股价,Acurx Pharmaceuticals, LLC*股市,Acurx Pharmaceuticals, LLC*股票价格,Acurx Pharmaceuticals, LLC*股票交易,Acurx Pharmaceuticals, LLC*股票购买,Acurx Pharmaceuticals, LLC*股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Acurx Pharmaceuticals, LLC*(ACXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Acurx Pharmaceuticals, LLC*(ACXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}